In February 2022, a recall at a major US formula plant sent parents scrambling. Shelves emptied, stores rationed purchases, and hospitals began improvising. Thousands of miles away, in Nairobi, some mothers were being handed free cans of formula as part of a malnutrition trial. Same product, opposite access. The juxtaposition raises uncomfortable questions about how we distribute infant nutrition across the wealth gradient, and what clinicians should do when the evidence and the shelves disagree.

A Tale of Two Shelves: Empty US Stores and Kenyan Trial Kits

The US shortage was sudden and severe. By May 2022, roughly 40% of infant formula was out of stock nationwide, according to some estimates. Parents drove hours, hoarded what they could, and turned to social media for leads. The cause was a single plant closure, but the effect was a cascade that exposed how little redundancy existed in the system.

Meanwhile, in Kenya, a different scene unfolded. Researchers distributed formula to mothers as part of a study aimed at reducing infant malnutrition. For many, the free samples were a lifeline. For others, they were a source of confusion and concern, especially when breastfeeding is the global gold standard. The same product, in one context a scarce commodity, in another a research tool.

The contrast is stark, but it is not new. Infant formula has long been a litmus test for global health inequity. In high-income countries, it is a convenience, sometimes a necessity. In low-income settings, it is often a marker of privilege or a tool in research. The shortage and the trials are two sides of the same coin, revealing how access to basic infant nutrition is anything but equal.

The Supply Chain That Broke: How US Shortages Emerged

The US formula market was already concentrated before the crisis. A handful of companies control the vast majority of supply, and a few plants produce most of the powder. When one of those plants, an Abbott Nutrition facility in Michigan, was shut down due to contamination concerns in February 2022, the system had no slack.

Regulatory hurdles slowed the reopening. The Food and Drug Administration (FDA) required extensive testing and inspections, which took months. Meanwhile, the shortage deepened. Stockpiling by panicked parents made things worse, creating a feedback loop that emptied shelves even faster.

The result was a crisis that lasted well into the summer of 2022. Some parents resorted to watering down formula, a dangerous practice that led to hospitalizations. Others turned to imported brands, which were not always nutritionally equivalent. The FDA eventually relaxed some rules to allow more imports, but the damage was done.

The episode highlighted a fundamental vulnerability: when a critical product is produced by a few, any disruption is amplified. It also showed that even wealthy nations can face infant nutrition insecurity, a problem usually associated with poverty. The lesson for clinicians was clear: formula access is not a given, even in affluent settings.

Beyond the Headlines: The Role of WIC and Government Programs

The US shortage was not experienced uniformly. The Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plays a crucial role in providing formula to low-income families, accounting for a significant share of formula purchases in the country. WIC contracts with specific manufacturers, which means that when a particular brand is recalled or unavailable, WIC recipients may not be able to switch to an alternative without a prescription or a waiver. During the 2022 crisis, many WIC families faced additional hurdles, as their benefits were tied to specific products that were out of stock. Some states implemented emergency waivers to allow substitutions, but the process was often slow and confusing. This administrative rigidity compounded the stress for families already struggling to find formula.

Moreover, the shortage highlighted the digital divide in access to information. Parents with reliable internet and social media connections could quickly locate stores with stock, while others relied on word of mouth or outdated information. Community health centers and food banks became informal distribution points, but their capacity was limited. The crisis revealed that formula access is not just a matter of supply, but also of information and support infrastructure. For clinicians, this means asking not only whether a family has formula, but also whether they have the resources to navigate the system—transportation, time, and digital connectivity—to obtain it.

Trial Samples in Nairobi: Research Ethics or Lifeline?

In Kenya, formula distribution has a different history. For decades, international agencies have warned against the promotion of breastmilk substitutes in low-income countries, citing risks of contamination, dilution, and the undermining of breastfeeding. The WHO International Code of Marketing of Breast-milk Substitutes, adopted in 1981, restricts the marketing of formula to protect breastfeeding.

Yet clinical trials continue to use formula as an intervention or control. In Nairobi, recent studies on malnutrition have included formula as part of the protocol, sometimes providing it free to participants. For mothers living in poverty, this can be a powerful incentive to enroll. But it also raises ethical questions about informed consent and coercion.

Proponents argue that such trials provide necessary data on how to treat malnutrition, and that providing formula is a form of benefit. Critics counter that it exploits vulnerable populations, especially when breastfeeding is a healthier and more sustainable option. The WHO code allows for formula use in medical need, but the line between research and marketing can blur.

The debate is not academic. In one Kenyan community, a mother told researchers she joined the trial because she could not afford to feed her baby otherwise. She did not fully understand the risks of formula, nor did she know that breastfeeding would have been recommended. Her story underscores the tension between research aims and participant welfare.

Ethical review boards are supposed to mitigate these issues, but their oversight is often weak in resource-limited settings. The result is a gray zone where good intentions can produce unintended harm. For clinicians, the takeaway is to ask hard questions about the trials they refer patients to, and to advocate for stronger protections.

The Microbiome and Beyond: What Formula Can and Cannot Do

Recent research has deepened our understanding of the differences between breast milk and formula, particularly regarding the infant microbiome. Breast milk contains a complex array of oligosaccharides, antibodies, and beneficial bacteria that shape the infant gut, influencing immune development and long-term metabolic health. Formula manufacturers have attempted to replicate some of these components—adding prebiotics, probiotics, and other bioactives—but the gap remains. A 2020 review in a leading pediatric journal noted that while some formulas show benefits in specific outcomes, such as reducing the risk of necrotizing enterocolitis in preterm infants, the overall evidence for long-term advantages is still limited. For clinicians, this means that while formula is a safe and adequate source of nutrition in most cases, it is not a perfect substitute for breast milk. The decision to use formula should be based on individual circumstances, and mothers should be supported in making informed choices without pressure or stigma.

In low-income settings, the microbiome question is even more critical. Contaminated water and improper preparation can introduce pathogens that disrupt the infant gut, leading to diarrhea and malnutrition. Even when formula is provided in trials, the infrastructure for safe preparation—clean water, fuel, and refrigeration—may be lacking. This is a key reason why the WHO emphasizes breastfeeding as the safest option in resource-limited environments. The trials in Kenya must therefore consider not just the nutritional content of formula, but the entire context in which it is used. A formula that is safe in a high-income setting may be hazardous in a low-income one, not because of the product itself, but because of the environment. This underscores the need for comprehensive education and support for mothers who receive formula in research settings, ensuring they have the knowledge and resources to use it safely.

Breastfeeding's Complicated Role in Both Settings

Breastfeeding is universally recommended by the WHO, and for good reason. It provides optimal nutrition, immune protection, and bonding. In low-income settings, it can be a matter of life or death, as formula contamination is a major cause of infant diarrhea and mortality. Yet breastfeeding is not always possible or sufficient, and formula is a legitimate alternative when needed.

In the US, breastfeeding rates are high, but many mothers rely on formula due to work demands, medical conditions, or personal choice. The shortage hit these families hard, forcing some to make impossible choices. The crisis also highlighted systemic failures: limited paid leave, inadequate workplace support, and a healthcare system that often fails to provide lactation support.

In Kenya, breastfeeding is the norm, but it is under pressure. Urbanization, maternal employment, and aggressive marketing by formula companies have contributed to a decline in exclusive breastfeeding. Trials that distribute formula can inadvertently reinforce the idea that formula is superior, undermining public health messages.

The evidence is clear: breastfeeding is best, but formula is sometimes necessary. The challenge is to support both, without stigmatizing mothers who cannot or choose not to breastfeed. Clinicians play a key role in this balance, but they often lack the training and resources to provide adequate support.

What the Data Say: Measuring Access and Outcomes

The data on formula access and infant outcomes are patchy, but they point to persistent inequities. In the US, the shortage lasted several months, with some areas hit harder than others. A study published in early 2023 found that low-income families were more likely to report difficulty finding formula, and that Black and Hispanic families were disproportionately affected.

In Kenya, trials have shown that formula can improve weight gain in malnourished infants, but the effects are often short-lived. A 2021 trial in Nairobi reported that infants who received formula had better short-term growth, but by six months, the gains had faded. The long-term outcomes are unknown, and the risks of contamination and infection remain.

Comparing the two settings is difficult, as the baseline conditions differ vastly. In the US, formula is a safe, regulated product; in Kenya, it is a potential hazard. The data also reflect different research priorities: US studies focus on access and supply chain, while Kenyan studies focus on efficacy and safety.

What is clear is that infant nutrition is a marker of broader health inequities. The shortage and the trials are not isolated events, but symptoms of a system that fails to ensure equitable access to essential resources. For clinicians, the data underscore the need to consider social determinants of health, not just clinical factors.

Clinical Practice Gap: Prescribing and Advising

Pediatricians in the US faced a unique challenge during the shortage: how to advise families when the recommended product was unavailable. Some switched to alternative brands, but not all were equivalent. Others provided recipes for homemade formula, a practice that is dangerous and not recommended. The lack of evidence-based guidance left clinicians improvising.

In Kenya, clinicians are often caught between the need to treat malnutrition and the pressure to promote breastfeeding. They may prescribe formula for medical reasons, but they also have to navigate the ethical minefield of trial participation. The evidence base for formula use in low-income settings is thin, and clinicians must weigh the benefits against the risks.

The gap between research and practice is evident in both settings. In the US, the shortage revealed a lack of contingency planning. In Kenya, trials have produced data that is not always translated into clinical guidelines. The result is that clinicians are left to make decisions based on incomplete information.

This gap is not new, but it is widening. As formula becomes more complex and specialized, the need for evidence-based guidance grows. Yet the research is often slow, underfunded, or focused on high-income settings. Clinicians need better tools to navigate the complexities of infant feeding, but they also need systemic changes that ensure access to safe, affordable formula when it is needed.

Bridging the Divide: Practical Takeaways for Clinicians

What can clinicians do, given these challenges? First, they can support breastfeeding when it is safe and feasible, but without judgment when it is not. This means providing lactation support, addressing barriers, and recognizing that formula is a legitimate choice.

Second, they can screen for formula insecurity, just as they would for food insecurity. Simple questions about access to formula can identify families at risk and connect them to resources. During the US shortage, some clinics set up hotlines and distribution points, but these were ad hoc.

Third, they can advocate for supply chain diversity and better regulation. The US shortage showed that a single point of failure can devastate families. Clinicians can push for policies that incentivize multiple producers and stockpiles, as well as for better oversight of trials in low-income settings.

Fourth, they can engage with the ethics of trial design. Clinicians who refer patients to trials should ask about the benefits and risks, and ensure that informed consent is truly informed. They can also support efforts to develop ethical frameworks for research in vulnerable populations.

Finally, they can work to reduce global inequities in infant nutrition. This means supporting breastfeeding promotion, but also advocating for access to safe formula where it is needed. The divide between the US and Kenya is not inevitable; it is the result of policy choices and resource allocation. Clinicians have a role in shaping those choices.

This article is for informational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider with questions about infant feeding.